Table 1.

Select new therapeutic strategies for patients with CHB under development.

Drug Names	Mechanism of Function	Effects	References
GLS4	Core binding	Data of 20 weeks demonstrated DNA level log decrease of 1.48–5.58 after administration (twice daily, BID)	[20]
ABI-H0731	Core binding	Data showed mean maximum NA level log reduction from baseline were 1.7, 2.1, and 2.8 in the 100, 200, and 300 mg dose group, respectively	[20,119]
RO7049389	Core binding	Median DNA level declines of 2.7 (200 mg, BID) and 3.2 (400 mg, BID) demonstrated at 28 days	[20,121]
REP 2165	HBsAg binding	Obviously higher percentages of CHB patients in REP 2165 group had reduction in HBsAg to below 1 IU/mL and HBsAg seroconversion during the first 24 weeks of TDF and PEG-IFN-α treatment	[20,122,123]
TG-1050	Transgene	HBV specific T cell responses were induced. Data at day 197 showed mean 0.45 log reduction in HBsAg levels	[124]
RO7020531	TLR7 agonist	Safety and tolerability in healthy Chinese donors with a 150 mg q.o.d.	[125]
GS-9688	TLR8	The antiviral efficacy of 3 mg/kg (weekly) was confirmed in a woodchuck study	[126]
JNJ3989	mRNA degradation	Data showed HBsAg level log reduction of 1.3–3.8	[127]
CRV431	Blocks NTCP	Data showed a significantly decreased liver HBV DNA levels with the treatment (50 mg/kg/day) for 16 days	[128]
GSK3389404	mRNA degradation	Data showed safe and target engagement, with dose-dependent reductions in HBsAg	[129]

HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; BID, twice daily; anti-HBs, anti-hepatitis B surface protein; TLR, Toll-like receptor; IU, infectious units; NTCP, sodium–taurocholate cotransporting polypeptide.